ReviewInternational journal of general medicine2026
Advances in the Diagnosis and Treatment of Rheumatoid Arthritis: From Pathological Mechanisms to Integrated Chinese and Western Medicine Therapeutic Strategies.
Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease whose exact cause remains unclear and is likely the result of multiple factors such as genetics and environmental influences. This disease primarily affects the joints and subsequently presents with extra-articular manifestations.The pathogenesis of RA is complex, and current research is yet to fully elucidate the underlying mechanisms. Consequently, investigations into the pathophysiological processes of RA remain in its early stages. Recent advancements in diagnostic methodologies and pharmacological interventions have significantly improved RA management. A growing number of novel therapeutic agents have been introduced, with methotrexate (MTX) remaining the cornerstone of first-line treatment. Furthermore, contemporary drug development efforts have increasingly focused on molecular medicine to enhance the therapeutic efficacy and safety profiles. Traditional Chinese medicine (TCM), with its unique theoretical system and therapeutic approaches, demonstrates promising potential in the treatment of RA and is increasingly attracting global attention. Clinical studies on Tripterygium wilfordii (thunder god vine) and preparations of Paeonia lactiflora (white peony) in rheumatoid arthritis and related conditions have also demonstrated certain efficacy and safety of Chinese herbal medicine. Currently, the integration of traditional Chinese and Western medical approaches for RA treatment is gaining wider acceptance. Therefore, this review will focus on exploring the potential of traditional Chinese medicine in improving RA outcomes, based on the diagnosis, epidemiology, and pathophysiological mechanisms of rheumatoid arthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.